|
|
左右侧结肠癌差异研究进展
|
Abstract:
结肠癌不是一个单一的疾病。因组织胚胎发育、肠道免疫及大肠菌群分布的差异性，左侧结肠癌和右侧结肠癌可能具有不同的生物学行为。在转移性结肠癌的辅助治疗中，左侧RAS野生型结肠癌使用抗EGFR单克隆抗体加化疗比较合理，右侧RAS野生型结肠癌的一线治疗方案可选择化疗加贝伐珠单抗。作者对左右侧结肠癌差异研究进展进行了综述。
Colon cancer is not a single disease. Due to differences in tissue embryonic development, intestinal immunity and distribution of coliforms, left colon cancer and right colon cancer may have different biological behaviors. In the adjuvant treatment of metastatic colon cancer, it is reasonable to use anti-EGFR monoclonal antibody plus chemotherapy for left RAS wild-type colon cancer, and chemo-therapy plus bevacizumab is the first-line treatment option for right RAS wild-type colon cancer. The author reviewed the research progress of the difference between left and right colon cancer.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [2] | Feng, R.M., Zong, Y.N., Cao, S.M. and Xu, R.H. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications, 39, 1-12. https://doi.org/10.1186/s40880-019-0368-6 |
| [3] | Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338 |
| [4] | Ben-son III, A.B., Venook, A.P., Cederquist, L., et al. (2017) Colon Cancer, Version 1.2017, NCCN Clinical Practice Guide-lines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 370-398.
https://doi.org/10.6004/jnccn.2017.0036 |
| [5] | Dekker, E., Tanis, P.K., Vleugels, J.L.A. and Kasi, P.M. (2019) Colorectal Cancer. The Lancet, 394, 1467-1480.
https://doi.org/10.1016/S0140-6736(19)32319-0 |
| [6] | Degro, C.E., Strozynski, R., Loch, F.N., et al. (2021) Sur-vival Rates and Prognostic Factors in Right- and Left-Sided Colon Cancer Stage I-IV: An Unselected Retrospective Sin-gle-Center Trial. International Journal of Colorectal Disease, 36, 2683-2696. https://doi.org/10.1007/s00384-021-04005-6 |
| [7] | Dienstmann, R., Vermeulen, L., Guinney, J., et al. (2017) Con-sensus Molecular Subtypes and the Evolution of Precision Medicine in Colorectal Cancer. Nature Reviews Cancer, 17, 79-92. https://doi.org/10.1038/nrc.2016.126 |
| [8] | Manes, M., Garcia-Gomes, M.S.A., Sandini, T.M., et al. (2019) Behavioral and Neurochemical Characterization of the mlh Mutant Mice Lacking Otoconia. Behavioural Brain Research, 359, 958-966.
https://doi.org/10.1016/j.bbr.2018.06.012 |
| [9] | Cai, Y., Rattray, N.J.W., Zhang, Q., et al. (2020) Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports, 10, Article No. 4905. https://doi.org/10.1038/s41598-020-61851-0 |
| [10] | De Renzi, G., Gaballo, G., Gazzaniga, P. and Nicolazzo, C. (2021) Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New In-sights. Oncology, 99, 135-143.
https://doi.org/10.1159/000510944 |
| [11] | Holch, J.W., Ricard, I., Stintzing, S., et al. (2017) The Relevance of Pri-mary Tumour Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials. Eu-ropean Journal of Cancer, 70, 87-98.
https://doi.org/10.1016/j.ejca.2016.10.007 |
| [12] | Arnold, D., Lueza, B., Douillard, J.Y., et al. (2017) Prognostic and Predictive Value of Primary Tumour Side in Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Chemotherapy and EGFR Directed Antibodies in Six Randomized Trials. Annals of Oncology, 28, 1713-1729. https://doi.org/10.1093/annonc/mdx175 |
| [13] | Zhao, B., Wang, L., Qiu, H., et al. (2017) Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer. Oncotarget, 8, 3980-4000. https://doi.org/10.18632/oncotarget.14012 |
| [14] | Nam, S.K., Yun, S., Koh, J., et al. (2016) BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metas-tasis. PLOS ONE, 11, e0151865.
https://doi.org/10.1371/journal.pone.0151865 |
| [15] | Zhao, B., Lopez, N.E., Eisenstein, S., et al. (2020) Synchro-nous Metastatic Colon Cancer and the Importance of Primary Tumor Laterality—A National Cancer Database Analysis of Right- versus Left-Sided Colon Cancer. The American Journal of Surgery, 220, 408-414. https://doi.org/10.1016/j.amjsurg.2019.12.002 |
| [16] | Petrelli, F., Tomasello, G., Borgonovo, K., et al. (2017) Prog-nostic Survival Associated with Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-Analysis. JAMA Oncology, 3, 211-219.
https://doi.org/10.1001/jamaoncol.2016.4227 |
| [17] | Laghi, L., Negri, F., Gaiani, F., et al. (2020) Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 21, Article No. 9680.
https://doi.org/10.3390/ijms21249680 |
| [18] | Yi, T., Zhang, Y., Ng, D.M., et al. (2021) Regulatory Network Analy-sis of Mutated Genes Based on Multi-Omics Data Reveals the Exclusive Features in Tumor Immune Microenvironment between Left-Sided and Right-Sided Colon Cancer. Frontiers in Oncology, 11, Article ID: 685515. https://doi.org/10.3389/fonc.2021.685515 |
| [19] | Wang, X., Duanmu, J., Fu, X., Li, T. and Jiang, Q. (2020) Ana-lyzing and Validating the Prognostic Value and Mechanism of Colon Cancer Immune Microenvironment. Journal of Translational Medicine, 18, 324.
https://doi.org/10.1186/s12967-020-02491-w |
| [20] | Li, X.Y., Wen, D.C., Li, X.K., et al. (2020) Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. Frontiers in Immunology, 11, Article No. 1678.
https://doi.org/10.3389/fimmu.2020.01678 |
| [21] | Cheng, Y., Ling, Z. and Li, L. (2020) The Intestinal Microbiota and Colorectal Cancer. Frontiers in Immunology, 11, Article ID: 615056. https://doi.org/10.3389/fimmu.2020.615056 |
| [22] | Rubinstein, M.R., Wang, X., Liu, W., et al. (2013) Fusobacte-rium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via Its FadA Adhe-sin. Cell Host & Microbe, 14, 195-206.
https://doi.org/10.1016/j.chom.2013.07.012 |
| [23] | Casasanta, M.A., Yoo, C.C., Udayasuryan, B., et al. (2020) Fusobacterium nucleatum Host-Cell Binding and Invasion Induces IL-8 and CXCL1 Secretion that Drives Colorectal Cancer Cell Migration. Science Signaling, 13, eaba9157.
https://doi.org/10.1126/scisignal.aba9157 |
| [24] | Cuevas-Ramos, G., Petit, C.R., Marcq, I., et al. (2010) Escherichia coli Induces DNA Damage in Vivo and Triggers Genomic Instability in Mammalian Cells. Proceedings of the National Academy of Sciences of the United States of America, 107, 11537-11542. https://doi.org/10.1073/pnas.1001261107 |
| [25] | Sears, C.L. and Pardoll, D.M. (2011) Perspective: Alpha-Bugs, Their Microbial Partners, and the Link to Colon Cancer. The Journal of Infectious Diseases, 203, 306-311. https://doi.org/10.1093/jinfdis/jiq061 |
| [26] | Tjalsma, H., Boleij, A., Marchesi, J.R. and Dutilh, B.E. (2012) A Bacte-rial Driver-Passenger Model for Colorectal Cancer: Beyond the Usual Suspects. Nature Reviews Microbiology, 10, 575-582. https://doi.org/10.1038/nrmicro2819 |
| [27] | Alhinai, E.A., Walton, G.E. and Commane, D.M. (2019) The Role of the Gut Microbiota in Colorectal Cancer Causation. International Journal of Molecular Sciences, 20, Article No. 5295. https://doi.org/10.3390/ijms20215295 |
| [28] | Phipps, O., Quraishi, M.N., Dickson, E.A., et al. (2021) Differ-ences in the On- and Off-Tumor Microbiota between Right- and Left-Sided Colorectal Cancer. Microorganisms, 9, 1108. https://doi.org/10.21203/rs.3.rs-226410/v1 |
| [29] | Zhong, M., Xiong, Y., Ye, Z., et al. (2020) Microbial Community Profiling Distinguishes Left-Sided and Right-Sided Colon Cancer. Frontiers in Cellular and Infection Microbiology, 10, Article ID: 498502.
https://doi.org/10.3389/fcimb.2020.498502 |
| [30] | Bach, S., Sluiter, N.R., Beagan, J.J., et al. (2019) Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. JNCI Cancer Spec-trum, 3, pkz042. https://doi.org/10.1093/jncics/pkz042 |
| [31] | Nicolazzo, C., Raimondi, C., Gradilone, A., et al. (2019) Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer. Cancers, 11, Article No. 1042. https://doi.org/10.3390/cancers11081042 |
| [32] | Taniguchi, H., Nakamura, Y., Kotani, D., et al. (2021) CIRCULATE-Japan: Circulating Tumor DNA-Guided Adaptive Platform Trials to Refine Adjuvant Therapy for Colo-rectal Cancer. Cancer Science, 112, 2915-2920.
https://doi.org/10.1111/cas.14926 |
| [33] | Kishiki, T., Kuchta, K., Matsuoka, H., et al. (2019) The Impact of Tumor Location on the Biological and Oncological Differences of Colon Cancer: Multi-Institutional Propensity Score-Matched Study. The American Journal of Surgery, 217, 46-52. https://doi.org/10.1016/j.amjsurg.2018.07.005 |
| [34] | Di Buono, G., Buscemi, S., Cocorullo, G., et al. (2021) Feasibility and Safety of Laparoscopic Complete Mesocolic Exci-sion (CME) for Right-Sided Colon Cancer: Short-Term Outcomes. A Randomized Clinical Study. Annals of Surgery, 274, 57-62. https://doi.org/10.1097/SLA.0000000000004557 |
| [35] | Yang, L., Xiong, Z., Xie, Q., et al. (2018) Prognostic Value of Total Number of Lymph Nodes Retrieved Differs between Left-Sided Colon Cancer and Right-Sided Colon Cancer in Stage III Patients with Colon Cancer. BMC Cancer, 18, Article No. 558. https://doi.org/10.1186/s12885-018-4431-5 |
| [36] | Cai, Y., Cheng, G., Lu, X., Ju, H. and Zhu, X. (2020) The Re-Evaluation of Optimal Lymph Node Yield in Stage II Right-Sided Colon Cancer: Is a Minimum of 12 Lymph Nodes Adequate? International Journal of Colorectal Disease, 35, 623-631. https://doi.org/10.1007/s00384-019-03483-z |
| [37] | Lee, L., Erkan, A., Alhassan, N., et al. (2018) Lower Survival after Right-Sided Versus Left-Sided Colon Cancers: Is an Extended Lymphadenectomy the Answer? Surgical Oncology, 27, 449-455.
https://doi.org/10.1016/j.suronc.2018.05.031 |
| [38] | Benson III, A.B., Venook, A.P., Al-Hawary, M.M., et al. (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Com-prehensive Cancer Network, 19, 329-359.
https://doi.org/10.6004/jnccn.2021.0012 |
| [39] | Neugut, A.I., Lin, A., Raab, G.T., et al. (2019) FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer, 18, 133-140. https://doi.org/10.1016/j.clcc.2019.01.005 |
| [40] | Fong, Y. (1999) Surgical Therapy of Hepatic Colorectal Metasta-sis. CA: A Cancer Journal for Clinicians, 49, 231-255.
https://doi.org/10.3322/canjclin.49.4.231 |
| [41] | Teo, J.Y., Allen, J.C., Ng, D.C., et al. (2016) A Systematic Review of Contralateral Liver Lobe Hypertrophy after Unilobar Selective Internal Radiation Therapy with Y90. HPB, 18, 7-12. https://doi.org/10.1016/j.hpb.2015.07.002 |
| [42] | Ruers, T., Van Coevorden, F., Punt, C.J.A., et al. (2017) Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. Journal of the National Cancer Institute, 109, djx015.
https://doi.org/10.1093/jnci/djx015 |
| [43] | Lévi, F.A., Boige, V., Hebbar, M., et al. (2016) Conversion to Resection of Liver Metastases from Colorectal Cancer with Hepatic Artery Infusion of Combined Chemotherapy and Systemic Ce-tuximab in Multicenter Trial OPTILIV. Annals of Oncology, 27, 267-274. https://doi.org/10.1093/annonc/mdv548 |
| [44] | Garajova, I., Balsano, R., Tommasi, C., et al. (2020) Synchronous and Metachronous Colorectal Liver Metastases: Impact of Primary Tumor Location on Patterns of Recurrence and Sur-vival after Hepatic Resection. Acta Biomedica, 92, e2021061. |
| [45] | Colloca, G.A., Venturino, A. and Guarneri, D. (2020) Different Variables Predict the Outcome of Patients with Synchronous versus Metachronous Metastases of Colorectal Cancer. Clinical and Translational Oncology, 22, 1399-1406.
https://doi.org/10.1007/s12094-019-02277-7 |
| [46] | Kafatos, G., Banks, V., Burdon, P., et al. (2021) Impact of Bi-omarkers and Primary Tumor Location on the Metastatic Colorectal Cancer First-Line Treatment Landscape in five Euro-pean Countries. Future Oncology, 17, 1495-1505.
https://doi.org/10.2217/fon-2020-0976 |
| [47] | Yoshino, T., Amold, D., Taniguchi, H., et al. (2018) Pan-Asian Adapted ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer: A JSMO-ESMO Initiative Endorsed by CSCO, KACO, MOS, SSO and TOS. Annals of Oncology, 29, 44-70. https://doi.org/10.1093/annonc/mdx738 |
| [48] | You, X.H., Jiang, Y.H., Fang, Z., et al. (2020) Chemotherapy Plus Bevacizumab as an Optimal First-Line Therapeutic Treatment for Patients with Right-Sided Metastatic Colon Cancer: A Meta-Analysis of First-Line Clinical Trials. ESMO Open, 4, e000605. https://doi.org/10.1136/esmoopen-2019-000605 |
| [49] | Temraz, S., Mukherji, D., Nassar, F., et al. (2021) Treatment Sequencing of Metastatic Colorectal Cancer Based on Primary Tumor Location. Seminars in Oncology, 48, 119-129. https://doi.org/10.1053/j.seminoncol.2021.05.001 |
| [50] | Chibaudel, B., André, T., Tournigand, C., et al. (2020) Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study. Clinical Colorectal Cancer, 19, 200-208.E1. https://doi.org/10.1016/j.clcc.2020.02.012 |
| [51] | Pietrantonio, F., Petrelli, F., Coinu, A., Ghilardi, M., et al. (2015) Predictive Role of BRAF Mutations in Patients with Advanced Colorectal Cancer Receiving Cetuximab and Pani-tumumab: A Meta-Analysis. European Journal of Cancer, 51, 587-594. https://doi.org/10.1016/j.ejca.2015.01.054 |
| [52] | Innocenti, F., Ou, F.S., Qu, X., et al. (2019) Mutational Analysis of Patients with Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tu-mor Mutational Burden for Patient Outcome. Journal of Clinical Oncology, 37, 1217-1227. https://doi.org/10.1200/JCO.18.01798 |
| [53] | Cremolini, C., Loupakis, F., Antoniotti, C., et al. (2015) FOLFOXIRI Plus Bevacizumab versus FOLFIRI Plus Bevacizumab as First-Line Treatment of Patients with Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study. The Lancet Oncology, 16, 1306-1315.
https://doi.org/10.1016/S1470-2045(15)00122-9 |
| [54] | Ducreux, M., Chamseddine, A., Laurent-Puig, P., et al. (2019) Molecular Targeted Therapy of BRAF-Mutant Colorectal Cancer. Therapeutic Advances in Medical Oncology, 11, Article ID: 1758835919856494.
https://doi.org/10.1177/1758835919856494 |
| [55] | Bao, X., Zhang, H., Wu, W., et al. (2020) Analysis of the Mo-lecular Nature Associated with Microsatellite Status in Colon Cancer Identifies Clinical Implications for Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e001437.
https://doi.org/10.1136/jitc-2020-001437 |
| [56] | André, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. https://doi.org/10.1056/NEJMoa2017699 |
| [57] | Overman, M.J., McDermott, R., Leach, J.L., et al. (2017) Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study. The Lancet Oncology, 18, 1182-1191. https://doi.org/10.1016/S1470-2045(17)30422-9 |
| [58] | Overman, M.J., Lonardi, S., Wong, K.Y.M., et al. (2018) Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instabil-ity-High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 36, 773-779. https://doi.org/10.1200/JCO.2017.76.9901 |
| [59] | Picard, E., Verschoor, C.P., Ma, G.W. and Pawelec, G. (2020) Relationships between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Frontiers in Immunology, 11, Article No. 369.
https://doi.org/10.3389/fimmu.2020.00369 |
